These studies have led to the rapid development of both anti-PD-1 and anti-PD-L1 checkpoint inhibitor therapies to block the PD-1: PD-L1 axis, which have since demonstrated significant improvements in patient outcomes in clinical trials for a range of cancers including HNC over the last five years. The gene discussed is PDCD1; the disease is cancer.